Overview
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Recent Publications
Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.
Journal Article Support Care Cancer · November 28, 2024 UNLABELLED: Hematopoietic cell transplantation (HCT) is a promising treatment for hematologic malignancies, but intensive conditioning leads to immunosuppression and susceptibility to healthcare-associated infections (HAI). Despite standard prevention meas ... Full text Link to item CiteFinancial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis.
Journal Article JCO Oncol Pract · March 2024 PURPOSE: We investigated the prevalence of financial toxicity in a population undergoing hematopoietic cell transplantation (HCT) evaluation and measured its impact on post-transplant clinical and health-related quality-of-life outcomes. MATERIALS AND METH ... Full text Link to item CiteA Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Journal Article Transplant Cell Ther · March 2023 Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ... Full text Link to item CiteRecent Grants
BEAT-MS
Clinical TrialCo Investigator · Awarded by Immune Tolerance Network · 2020 - 2028BEAT-MS
Clinical TrialCo Investigator · Awarded by Benaroya Research Institute at Virginia Mason · 2021 - 2025An Open-label Pilot Multicenter Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms
Clinical TrialPrincipal Investigator · Awarded by ADC Therapeutics Sarl · 2020 - 2025View All Grants
Education, Training & Certifications
Wake Forest University ·
1983
M.D.
Wake Forest University ·
1979
M.S.